Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a fixed-dose combination medication for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.Vosevi was approved for medical use in the United States and in the European Union in July 2017. Vosevi is sold by Gilead Sciences. References External links Combination drugs NS3/4A protease inhibitors NS5B (polymerase) inhibitors NS5A inhibitors